PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate the extent and trends of personal payments from pharmaceutical companies to cardiologists board-certified by the Japanese Circulation Society.
METHODS: A retrospective analysis study using data from a publicly available database.
METHODS: The study focused on payments to cardiologists in Japan.
METHODS: All 15 048 cardiologists who were board-certified by the Japanese Circulation Society as of 2021.
METHODS: The primary outcome was the extent of personal payments to cardiologists in 2016-19. Secondary outcomes included the analysis of trends in these payments over the same period.
RESULTS: Of all 15 048 board-certified cardiologists, 9858 (65.5%) received personal payments totaling $112 934 503 entailing 165 013 transactions in 2016-19. The median payment per cardiologist was $2947 (IQR, $1022-$8787), with a mean of $11 456 (SD, $35 876). The Gini Index was 0.840, indicating a high concentration of payments to a small number of cardiologists. The top 1%, 5% and 10% of cardiologists received 31.6%, 59.4% and 73.5% of all payments, respectively. There were no significant trends in the number of cardiologists receiving payments or number of payments per cardiologist during the study period.
CONCLUSIONS: More than 65% of Japanese cardiologists received personal payments from pharmaceutical companies over the 4-year study period. Although the payment amount was relatively small for the majority of cardiologists, a small number of cardiologists received the vast majority of the payments.
METHODS: A retrospective analysis study using data from a publicly available database.
METHODS: The study focused on payments to cardiologists in Japan.
METHODS: All 15 048 cardiologists who were board-certified by the Japanese Circulation Society as of 2021.
METHODS: The primary outcome was the extent of personal payments to cardiologists in 2016-19. Secondary outcomes included the analysis of trends in these payments over the same period.
RESULTS: Of all 15 048 board-certified cardiologists, 9858 (65.5%) received personal payments totaling $112 934 503 entailing 165 013 transactions in 2016-19. The median payment per cardiologist was $2947 (IQR, $1022-$8787), with a mean of $11 456 (SD, $35 876). The Gini Index was 0.840, indicating a high concentration of payments to a small number of cardiologists. The top 1%, 5% and 10% of cardiologists received 31.6%, 59.4% and 73.5% of all payments, respectively. There were no significant trends in the number of cardiologists receiving payments or number of payments per cardiologist during the study period.
CONCLUSIONS: More than 65% of Japanese cardiologists received personal payments from pharmaceutical companies over the 4-year study period. Although the payment amount was relatively small for the majority of cardiologists, a small number of cardiologists received the vast majority of the payments.
摘要：
目的：评估制药公司向日本循环学会认证的心脏病专家委员会支付个人费用的程度和趋势。
方法：使用公开数据库数据的回顾性分析研究。
方法：该研究的重点是向日本的心脏病专家支付费用。
方法：截至2021年，所有15048名心脏病专家均获得了日本循环学会的董事会认证。
方法：主要结果是2016-19年度心脏病专家的个人支付程度。次要结果包括对同期这些付款趋势的分析。
结果：在所有15048名获得董事会认证的心脏病专家中，9858（65.5%）在2016-19年度收到的个人付款总额为112934503美元，涉及165013笔交易。每位心脏病专家的薪酬中位数为2947美元(IQR，$1012-$8787），平均值为11456美元(SD，$35876）。基尼系数为0.840，表明支付给少数心脏病专家的费用高度集中。前1%，5％和10％的心脏病专家接受了31.6％，所有付款的59.4%和73.5%，分别。在研究期间，接受付款的心脏病专家数量或每位心脏病专家的付款数量没有显着趋势。
结论：在4年的研究期间，超过65%的日本心脏病专家从制药公司获得了个人报酬。尽管大多数心脏病专家的付款金额相对较小，少数心脏病专家收到了绝大多数的付款。
方法：使用公开数据库数据的回顾性分析研究。
方法：该研究的重点是向日本的心脏病专家支付费用。
方法：截至2021年，所有15048名心脏病专家均获得了日本循环学会的董事会认证。
方法：主要结果是2016-19年度心脏病专家的个人支付程度。次要结果包括对同期这些付款趋势的分析。
结果：在所有15048名获得董事会认证的心脏病专家中，9858（65.5%）在2016-19年度收到的个人付款总额为112934503美元，涉及165013笔交易。每位心脏病专家的薪酬中位数为2947美元(IQR，$1012-$8787），平均值为11456美元(SD，$35876）。基尼系数为0.840，表明支付给少数心脏病专家的费用高度集中。前1%，5％和10％的心脏病专家接受了31.6％，所有付款的59.4%和73.5%，分别。在研究期间，接受付款的心脏病专家数量或每位心脏病专家的付款数量没有显着趋势。
结论：在4年的研究期间，超过65%的日本心脏病专家从制药公司获得了个人报酬。尽管大多数心脏病专家的付款金额相对较小，少数心脏病专家收到了绝大多数的付款。
